We know that for these patients with obesity, diabetes, CKD, cardiovascular disease [CVD], these are really not isolated or distinct entities. However, the research comes at a time when supply chain issues for the GLP-1 receptor agonists have been pronounced and prolonged
Clues exist that may help explain the distinct results of liraglutide and exenatide
Plans also need to consider where the drugs will be placed on their formulary
However, oral formulations have different bioavailability profiles and may require different dosing schedules
What's the difference between ICD-10 and SNOMED CT for coding diabetes complications
The amino acid sequence is the same compound that Novo Nordisk has published, but the research-grade material supplied here is not equivalent to any Health Canada-authorized semaglutide product, is not produced under the same regulatory framework, and is not a substitute for the authorized formulations